A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders

Key Findings:  There is a lack of evidence on the therapeutic effects of cannabinoids for amyotrophic lateral sclerosis and dystonia. Although trials with positive findings were identified for anorexia nervosa, anxiety, PTSD, psychotic symptoms, agitation in Alzheimer’s disease and dementia, Huntington’s disease, and Tourette syndrome, and dyskinesia in Parkinson’s disease, definitive conclusion on its efficacy could not be drawn.

Type of Study:  Meta-analysis

Study Result:  Positive

Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), Pharma THC, Pharma THC:CBD

Phytocannabinoid Source:  Not Applicable

Chemotype:  Chemotype I, Chemotype II

Form of Administration:  Ingestion, Sublingual

Dosage: Dronabinol (Marinol) 2.5 mg, 5 mg, 10 mg (Oral capsule) Nabilone (Cesamet) 1 mg (Oral capsule) Nabiximols (Sativex) 2.7 mg THC and 2.5 mg CBD, per spray (100 μl) (Oromucosal spray) CBD (Cannabis plant extract) Oral capsule (Variable dosages) THC (Namisol) (Cannabis plant extract) Oral capsule (Variable dosages)

Study Location(s):  Singapore

Year of Pub:  2018

Link to study